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Accepted 30 October 2012AbstractObjective: To analyze the performance of the first trimester Down syndrome screening in a single medical center in Northern Taiwan.
Materials and methods: From April 1999 to June 2012, a total of 25,104 pregnant women at gestational age of 10 weeks to 13 weeks 6 days
received first trimester “combined test” for Down syndrome screening. The test combines the ultrasound scan of nuchal translucency thickness
and maternal biochemical serum levels of pregnancy-associated plasma protein A (PAPP-A) and free beta-human chorionic gonadotropin (b-
hCG). A positive screen was defined as an estimated Down syndrome risk 1/270, and either chorionic villous sampling or amniocentesis was
performed for fetal chromosomal analyses.
Results: Seventy-eight of the 25,104 pregnancies were proven to have fetal chromosome anomalies. The detection rates for trisomy 21, trisomy
18, Turner syndrome, and other chromosome anomalies were 87.5% (21/24), 69.2% (9/13), 81.8% (9/11), and 60% (18/30), respectively, with a
false positive rate (FPR) of 5.4% (1353/25,026). Further evaluation of the detection rates for trisomy 21, by gestational age at 11, 12, and 13
weeks, were 92.3%, 87.5%, and 66.7%, respectively.
Conclusion: The first trimester combined test is an effective screening tool for Down syndrome detection with an acceptable low false positive
rate. The best timing of screening will be between 11 and 12 weeks’ gestation.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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In 1984, Merkatz et al found an association between second
trimester low maternal serum level of alpha-fetoprotein (AFP)
and fetal Down syndrome [1]. Later, the double test that added
human chorionic gonadotropin (hCG) was introduced as a
prenatal screening tool for Down syndrome in the second
trimester, and this test has been a popular screening method in* Corresponding author. Prenatal Diagnosis Center, Department of Obstet-
rics and Gynecology, Cathay General Hospital, 280 Renai Road, Section 4,
Taipei, Taiwan.
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1028-4559/$ - see front matter Copyright  2013, Taiwan Association of Obstetri
http://dx.doi.org/10.1016/j.tjog.2013.10.012Taiwan since 1994. However, the detection rate for Down
syndrome of the double test reported by Taiwan Down Syn-
drome Screening Group was approximately 56.5%, with a
false positive rate (FPR) of 5.3% [2,3]. The first trimester
combined test, which measures the thickness of nuchal
translucency, and serologic tests, which measure pregnancy-
associated plasma protein A (PAPP-A) and free beta-hCG
(b-hCG) [4], have been proven as effective screening
methods for Down syndrome, with a higher detection rate of
85e90% for an FPR of 5% [5e18]. Since April 1999, the first
trimester combined test has been offered to every pregnant
woman who came to Cathay General Hospital, Taipei, during
10e13 weeks of gestation. Recently, a second trimester
quadruple test, that added unconjugated estriol (uE3) and
inhibin A to the double test, has been developed for a highercs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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quadruple test is reserved as an alternative test for pregnant
women whose first prenatal visits are beyond 13 weeks and 6
days’ gestation in the hospital. The aim of this study was to
evaluate the performance of the first trimester combined test
for Down syndrome detection.
Materials and methods
From April 1999 to June 2012, the first trimester combined
test was routinely provided for pregnant women who came to
Cathay General Hospital for prenatal care. The test involves
measuring fetal nuchal translucency (NT) thickness and
maternal serum levels of free b-hCG and PAPP-A at 10 weeks
to 13 weeks 6 days of gestation. Fetal NT was measured ac-
cording to the established criteria published by the fetal
medicine foundation of the United Kingdom. The
crownerump lengths of fetuses were measured to determine
the gestational ages. Maternal serum levels of free b-hCG and
PAPP-A were determined simultaneously using a microtiter
plate enzyme-linked immunosorbent assay (ELISA), accord-
ing to the manufacturer’s protocol (Genemed Biotechnologies,
South San Francisco, CA, USA). The values of NT, PAPP-A,
and free b-hCG were divided by their respective day-specific
median levels to determine the multiples of the median
(MoM) of each marker. Down syndrome risk was calculated
using Alpha Software (Logical Medical Systems, London,
UK) based on a multivariate Gaussian distribution as described
by Wald et al [21]. A positive screening result was defined as
an estimated Down syndrome risk 1/270.
All chromosome analyses were carried out in the Prenatal
Diagnosis Center of Cathay General Hospital in Taiwan. For
cultured chorionic villous tissue and amniotic fluid cells, four
primary cultures were performed using an in situ method with
CHANG MEDIUM BMC (Irvine Scientific, Santa Ana, CA,
USA). Microscopic analysis of Giemsa-stained chromosome
banding used the rules for metaphase selection and colony
definition as defined by Moertel et al [22]. The data of the
combined test was extracted from a computerized Birth
Database of Cathay General Hospital that was established by
specially trained nurses in 1999. The research and ethics
committee of Cathay General Hospital approved this study.
Results
Among the 25,104 pregnancies receiving the combined test
during 10e13 weeks of gestation, there were 3326 (13%) at 10Table 1
Screening data of different fetal chromosome abnormalities.
Trisomy 21 (n ¼ 24) Trisomy 1
Mean NT thickness (MoM) 2.0 3.5
Mean PAPP-A (MoM) 0.5 0.6
Mean Free b-hCG (MoM) 1.8 0.7
Affected numbers 24 13
Detection rate (5% FPR) 87.5% 69.2%
b-hCG ¼ beta human chorionic gonadotropin; FPR ¼ false positive rate; NT ¼ n
a Others ¼ other chromosome abnormality.weeks, 10,222 (41%) at 11 weeks, 8376 (33%) at 12 weeks,
and 3180 (13%) at 13 weeks of gestation. The mean gesta-
tional age, maternal age, and maternal weight were 83 days,
29 years and 55 kg, respectively. There were 785 (3.1%)
women >35 years of age and 304 (1.2%) women with mul-
tiple gestations. Among the multiple gestations, 302 women
had twins and two had triplets. In total, 78 cases of chromo-
somal abnormality were identified. Among them, there were
24 cases of trisomy 21, 13 cases of trisomy 18, 11 cases of
Turner syndrome, and 30 cases of chromosome anomalies
including mosaicism, microdeletion, balanced and unbalanced
chromosome structural anomalies, and other aneuploidy. With
the cut-off value of 1/270, there were 1417 positive-screen
pregnancies which occurred in 5.3% (1280/24,319) of
women <35 years of age and 17.5% (137/785) of women of
advanced maternal age. The detection rates for trisomy 21,
trisomy 18, Turner syndrome, and other chromosome anom-
alies were 87.5% (21/24), 69.2% (9/13), 81.8% (9/11), and
60% (18/30), respectively (shown in Table 1). In trisomy 21,
the MoM of maternal serum PAPP-A is 0.5 and free b-hCG is
1.8. In trisomy 18, the mean MoM of PAPP-A is 0.6 and free
b-hCG is 0.7. In Turner syndrome, the mean MoM of PAPP-A
is 0.5 and free b-hCG is 1.8. The detection rates for trisomy 21
at 11, 12, and 13 weeks were 92.3% (12/13), 87.5% (7/8), and
66.7% (2/3), respectively, with corresponding FPR values of
5.7%, 5.2%, and 3.9% (shown in Fig. 1).
Discussion
Two large clinical trials have demonstrated the effective-
ness of first trimester combined test for Down syndrome
screening. One was the SURUSS trial [14], including
47,053women primarily from the UK, which reported an 85%
Down syndrome detection rate of the first trimester combined
test under the FPR of 4.3%. The other one was the FASTER
trial [5], including 38,000 women in the United States, which
reported a similar result of an 85% detection rate under the
FPR of 4.8%. This study showed that, with an FPR of 5.4%,
the combined test could reach a Down syndrome detection rate
of 87.5%, which was similar to the effectiveness of the two
large series studies mentioned above.
The first trimester biochemical markers in this study showed
that the mean values of free b-hCG and PAPP-A of 1.2 MoM
(both in unaffected pregnancies) were higher than those which
had been reported by the western countries [23,24], but were
similar to a report of a predominantly Chinese population [9]. In
trisomy 21 pregnancies, the mean MoM value decreased to 0.58 (n ¼ 13) Turner syndrome (n ¼ 11) Othersa (n ¼ 30)
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Fig. 1. The detection rate of Down syndrome by gestational week.
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population, which is consistent with what had been found in the
Caucasian population (0.5 MoM for PAPP-A and 2.0 MoM for
freeb-hCG) [25].Malone et al (2005) reported that the detection
rates of first trimester Down syndrome screening at 11, 12, and
13 weeks were 87%, 85%, and 82%, respectively, with an FPR
of 5% [5]. They proposed that the best timing to use the com-
bined test is during 11e12 gestational weeks, because the dif-
ference of PAPP-A levels between trisomic and euploid
pregnancies is greater than the difference of free b-hCG at this
period of time. In this study, we also demonstrated that therewas
a higher detection rate (92.3%) at 11 gestational weeks, with an
FPR of 5.7%. Therefore, we suggest that pregnant women
should receive the first trimester combined test during 11e12
weeks of gestation.
Fetal NT is an effective ultrasound marker for Down syn-
drome screening. However, the effectiveness of the combined
test mainly depends on the accuracy and quality of NT mea-
surement. Previous publications indicated that NT thickness
increases between 10 and 14 weeks of gestation due to physi-
ological change. Pajkrt et al (1998) reported that NT thickness
increased from 0.7 mm at 10 weeks of gestation to a peak of
1.7 mm at 13 weeks of gestation, and then declined to 1.0 mm at
14 weeks [26]. In this study, we found that the median NT
thickness also increased with the increase of gestation week
(0.97 mm for 10 weeks, 1.15 mm for 11 weeks, 1.35 mm for 12
weeks, and 1.55 mm for 13 weeks), which was consistent with
the data above. The medianMoM of NTwas 1.04, thus we had a
good quality control on fetal NT measurement.
The second trimester Down syndrome screening evolved
from the previous double test to quadruple test, and is
currently the mainstream test which can reach a higher
detection rate of 75w80% with an FPR of 5% [5,19,20]. The
test has been implemented in our hospital since 2008, and is
provided to pregnant women whose first prenatal visit was
beyond 13 gestational weeks or who have an intermediate risk
(1/270w1/1000) in the combined test. At present, 3879
women received the quadruple test and the detection rate for
Down syndrome was 83.3% (5/6) with an FPR of 6.3%.
Although the second trimester quadruple test is not as effective
as first trimester combined test, these two tests can be com-
bined together as an integrated or sequential test. Both tests
can yield a higher detection rate for Down syndrome to 95%
with a 5% FPR and reduce the fetal loss rate associated with
an invasive procedure [5].Circulating cell-free fetal DNA from maternal plasma has
offered a new approach for noninvasive prenatal diagnosis for
fetal aneuploidies including trisomy 21, trisomy 18, trisomy
13, and sex chromosome numerous anomalies [27e29]. The
Noninvasive Fetal Trisomy (NIFTY) test has yield
98.58w100% sensitivity and 97.95w100% specificity for
Trisomy 21[30e33]. This test has two advantages. First, fetal
DNA from maternal blood can be evaluated as early as 8
gestational weeks, which is earlier than the current first
trimester Down syndrome screening. Second, there is no
procedure related fetal loss associated with amniocentesis or
chorionic villous sampling. However, not all healthy providers
have the equipment and laboratory for the cell-free fetal DNA
analysis, and the cost is much higher than Down syndrome
screening, especially in Taiwan.
In conclusion, the first trimester combined test is an
effective screening tool for Down syndrome detection, with an
acceptable low false positive rate. The best timing of screening
will be between 11 and 12 weeks’ gestation.References
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